New hope for advanced stomach cancer: targeted drug enters final testing phase
NCT ID NCT07518147
First seen Apr 14, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests a new drug called BL-M05D1 in people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and has stopped responding to initial treatment. About 438 adults will be randomly assigned to receive either BL-M05D1 or a standard treatment chosen by their doctor. The goal is to see if the new drug helps people live longer or slows cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.